Zacks Research Weighs in on Puma Biotechnology, Inc.’s FY2025 Earnings (NASDAQ:PBYI)

Puma Biotechnology, Inc. (NASDAQ:PBYI) – Stock analysts at Zacks Research cut their FY2025 earnings estimates for shares of Puma Biotechnology in a research note issued to investors on Thursday, September 26th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will post earnings of $0.19 per share for the year, down from their previous estimate of $0.22. The consensus estimate for Puma Biotechnology’s current full-year earnings is $0.25 per share.

Puma Biotechnology (NASDAQ:PBYI) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.01. The company had revenue of $47.10 million for the quarter, compared to analysts’ expectations of $43.99 million. Puma Biotechnology had a net margin of 4.01% and a return on equity of 18.36%. During the same period in the previous year, the company posted $0.05 EPS.

Several other equities research analysts have also commented on PBYI. StockNews.com lowered shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 13th. HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Puma Biotechnology in a research report on Friday, August 2nd.

Puma Biotechnology Price Performance

Shares of NASDAQ PBYI opened at $2.60 on Monday. The firm has a market capitalization of $125.42 million, a P/E ratio of 7.88 and a beta of 1.09. Puma Biotechnology has a one year low of $2.13 and a one year high of $7.73. The company’s fifty day moving average is $2.91 and its two-hundred day moving average is $3.80. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.23 and a current ratio of 1.32.

Insider Buying and Selling

In related news, Director Michael Patrick Miller sold 23,358 shares of the business’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $3.49, for a total value of $81,519.42. Following the sale, the director now directly owns 47,000 shares in the company, valued at approximately $164,030. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, Director Michael Patrick Miller sold 23,358 shares of the business’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $3.49, for a total value of $81,519.42. Following the sale, the director now directly owns 47,000 shares in the company, valued at approximately $164,030. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Alan H. Auerbach sold 21,920 shares of the business’s stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $3.70, for a total transaction of $81,104.00. Following the completion of the sale, the chief executive officer now owns 7,063,515 shares in the company, valued at $26,135,005.50. The disclosure for this sale can be found here. Insiders have sold 52,032 shares of company stock worth $187,613 in the last three months. Corporate insiders own 23.70% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PBYI. Victory Capital Management Inc. purchased a new position in Puma Biotechnology in the 2nd quarter valued at about $54,000. SG Americas Securities LLC purchased a new position in Puma Biotechnology in the 1st quarter valued at about $57,000. The Manufacturers Life Insurance Company purchased a new position in Puma Biotechnology in the 2nd quarter valued at about $58,000. Rhumbline Advisers lifted its holdings in Puma Biotechnology by 2,309.9% in the 2nd quarter. Rhumbline Advisers now owns 50,270 shares of the biopharmaceutical company’s stock valued at $164,000 after purchasing an additional 48,184 shares in the last quarter. Finally, Squarepoint Ops LLC lifted its holdings in Puma Biotechnology by 17.7% in the 2nd quarter. Squarepoint Ops LLC now owns 71,391 shares of the biopharmaceutical company’s stock valued at $233,000 after purchasing an additional 10,757 shares in the last quarter. 61.29% of the stock is currently owned by hedge funds and other institutional investors.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.